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Multiple organ failure – death of consumer protection?
H A Steinman, M R Jobson 
The enormously profitable complementary medicines, dietary 
supplements and traditional medicines markets are largely 
unregulated internationally and in South Africa. Attempts 
to ensure that consumers are not exposed to harmful or 
ineffective products have met with varying success around the 
world.
International perspective
The USA introduced its Dietary Supplements Health and 
Education Act (DSHEA) in 1994.1 This was seen as a precedent 
in many countries, including South Africa. In Canada a 
Natural Health Products Directorate as part of the Health 
Products and Food Branch of Health Canada was created.2 In 
2004, the Natural Health Product Regulations (NHPR), under 
Canada’s Food and Drugs Act, became a reality. Rather than 
fully regulating these products as drugs, or leaving them 
virtually unregulated (as is done in the USA), the NHPR were 
a regulatory compromise: implementing manufacturing quality 
and safety standards, while significantly relaxing the standards 
for product efficacy claims.3
The UK’s Medicines and Healthcare products Regulatory 
Agency (MHRA) introduced the Traditional Herbal 
Registration (THR) certification mark to indicate that a herbal 
medicine that has been registered under the UK’s THR 
scheme meets the criteria laid down by the Traditional Herbal 
Medicinal Products Directive.4 
In New Zealand a 2-month consultation was held in early 
2010 because, according to Associate Health Minister Dr 
Jonathan Coleman, the current legislation governing natural 
health products is outdated, inadequate and quite restrictive.5 
The intention in New Zealand is to draft a Natural Health 
Products Bill during 2010.5 In Australia, the Therapeutic Goods 
Authority’s listing system has been widely implemented,6 
but has been criticised because it does not adequately assess 
efficacy.7 
It is difficult to ascertain what the situation is in India, where 
traditional medicines and ‘conventional’ or ‘Western’ medicines 
have coexisted for many years. Similarly, in China it is difficult 
to determine the extent of regulation (or not) of traditional 
Chinese medicines. Unfortunate examples of adulteration of 
medicines imported from China – such as Simply Slim in South 
Africa, containing sibutramine – have cast suspicion on many 
products imported as complementary medicines or dietary 
supplements.
In South Africa the consumer of natural health products 
should be protected from harmful or even useless products by 
several organs of state: the Medicines Control Council (MCC), 
the South African Pharmacy Council (SAPC), and the Public 
Protector. The Advertising Standards Authority of South Africa 
(ASA) is a body created by the industry to protect consumers 
from misleading advertising claims. We provide examples 
showing how each of these organs has failed South African 
consumers.
The advertising standards authority
The weight-loss product Peel Away the Pounds, declared 
‘dead’ by the USA Federal Trade Commission (FTC), was 
transplanted by Homemark into the South African market. 
The scientific panel of the FTC had in 2004 unanimously found 
that the pilot study was inadequate to support the claims.8,9 
A complaint laid with the ASA in 2005 by the first author 
was dismissed following substantiation by a pharmacist, Dr 
Beverley Summers, who argued that the study was sufficient 
proof of efficacy, and that a kelp transdermal patch was 
pharmacologically active (despite no scientific proof).10 Four 
internationally recognised experts who evaluated the original 
study agreed with us that the study was inadequate to support 
the claims being made for the product.11 Subsequent arbitration 
by Professor René Blaauw and Dr Edelweiss Wentzel-Viljoen 
found in favour of the complainant,12 and the product was 
removed from the market 3 years after the initial complaint.
Homemark then marketed another product ruled against by 
an FTC scientific panel: Slim Coffee with the ingredient Citrus 
aurantium,13 which contains synephrine. Dr Summers again 
substantiated14 the study and supported the weight-loss claims 
despite the FTC ruling.15,16 The research entity and its address 
could not be verified, not even by the Italian consulate.
Weight-loss products are defined as medicines and were 
called up in 1972 by the Medicines Control Council for 
registration.17 The complementary medicines call-up of 2002 
did not specifically exempt products affected by the 1972 
call-up.18 This fact was ignored by Dr Summers, who failed to 
point out that Slim Coffee should not have been submitted to 
the MCC for an abbreviated registration (as a complementary 
medicine), but for ‘full’ registration as a medicine. 
The World Health Organization (WHO) Pharmaceuticals 
Newsletter reporting on C. aurantium warned of, among others, 
‘15 reports … of cardiovascular adverse reactions, 10 of which 
were serious and included one report of myocardial infarction’ 
in Canada.19 Serious adverse reactions to C. aurantium have 
also been published in South Africa.20,21 Nevertheless the 
ASA accepted Dr Summers’ substantiation and ruled against 
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the complaint. Following a request for arbitration of the 
ASA ruling dismissing the complaint against Slim Coffee, 
Homemark stated that they had withdrawn it because of 
‘safety concerns’ and introduced a new formulation of Slim 
Coffee, now containing guarana and Caralluma fimbriata (CF) – 
again substantiated by Dr Beverley Summers. A new complaint 
was laid with the ASA with the request that Dr Summers’ 
status with the ASA as a ‘credible expert’ be revoked. Both 
aspects of the complaint were upheld. Homemark appealed 
the ‘credible expert’ ruling, but this was rejected by the appeal 
committee. Following a second appeal to the final appeal 
committee, Judge Mervyn King ruled in favour of Homemark, 
effectively allowing Dr Summers to substantiate further 
Homemark products despite the history above.
Dr Summers’ substantiation of the new Slim Coffee product 
was accepted by the ASA’s appeal committee in spite of 
being supported by only two studies,22,23 which the European 
Food Safety Authority ‘found … failed to establish a cause 
and effect relationship between the ingredient (CF) and the 
claimed benefit’.24 These were the same studies provided 
to Dr Summers by Homemark and substantiated by her. 
Our argument that to reproduce the dose of CF used in the 
inconclusive CF studies would require a consumer to spend 
R1 799.40 over 2 months was dodged. The appeal committee 
ignored previous rulings of the ASA, which stated that a 
product cannot be substantiated on the basis of ingredients 
alone but on evidence of the efficacy of the product as a whole.  
The South African Pharmacy council
Because of Dr Summers’ persistent substantiation of ‘bogus’ 
Homemark products, a complaint of ‘unprofessional conduct’ 
was laid with the SAPC in May 2009. The SAPC dismissed the 
complaint 10 months later, responding that where a pharmacist 
provides evidence as an expert before an independent judicial 
tribunal, such as the ASA, Council should not review such 
evidence on the basis of misconduct, that it is up to the 
‘independent tribunal … whether to accept or reject such 
expert evidence’, and that ‘the onus rests on the other party 
to argue whether such expert evidence should be accepted’. 
The SAPC were concerned that the ‘potential would be created 
that pharmacists would become reluctant to provide expert 
evidence to independent tribunals and in a court of law should 
Council adjudicate such matters in terms of unprofessional 
conduct’.25 The SAPC (a science-based statutory council) 
therefore did not want to override any decision of the ASA 
(an industry-based, non-scientific, non-statutory ‘authority’ 
and not in fact a judicial tribunal). This decision creates a 
precedent that allows pharmacists to substantiate claims made 
for unregistered and unregulated products despite insufficient 
evidence for their claims. Consumers are therefore placed at 
risk of harm, financially and to their health.
The Medicines control council
The most critical organ failure is that of the MCC, which has 
the statutory responsibility to ensure that all medicines and 
related substances available to the public meet the criteria of 
quality, safety and efficacy.26 Inspectors from the Department 
of Health (DOH) are responsible for the enforcement of 
the Medicines Act. The ASA can rule on misleading claims, 
but cannot prevent any product from being sold, penalise 
miscreants or rule on product safety. Several letters of 
complaint submitted about other products to senior members 
of the MCC/Medicines Regulatory Affairs Cluster of the DOH 
remain unanswered.
In February 2010 the MCC suspended the sale of Simply 
Slim, as it had been found to contain sibutramine. The 
MCC did not ‘ban’ the product in terms of section 23 of the 
Medicines Act, but seemingly used a sub-clause of section 15 
of the Act. Simply Slim re-launched their product using a local 
manufacturer and a system for customers to validate that it 
was a genuine product. It appears that no clinical evidence of 
the product’s safety or efficacy had been provided to the MCC.
The Public Protector
In September 2009, following a complaint directly to the 
MCC regarding a homeopathic product MODUL8, which 
claimed to treat AIDS, going unanswered, the Public Protector 
was approached for intervention. In January 2010 the Public 
Protector closed the file following the response from the 
MCC, which stated among other things: ‘In February 2008, 
the Medicines Control Council (MCC) ruled against Canova, 
a product similar to MODUL8. The Council requested the 
company marketing Canova to withdraw the product from 
the market because the product safety profile could not be 
substantiated. The company has since appealed the decision of 
Council in terms of the provision of section 24 of the Medicines 
and Related Substances Act, 1965. The MCC is still awaiting for 
[sic] the ruling by the appeal committee. The decision of the 
appeal committee on Canova will be applied to MODUL8.’27 
No further information has been received.
conclusion
Multiple organ failure has clearly resulted in an inability to 
efficiently clear or reject deleterious medicines and substances, 
resulting in financial and health trauma to consumers, with 
possible consequences including unnecessary deaths.
We await with interest the implementation of the Consumer 
Protection Act28 and wonder whether the National Consumer 
Council will resuscitate consumer protection in the area of 
health products, or whether it too will succumb to organ 
failure.
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